Compare AbCellera Biologics Inc (ABCL) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Lockheed Martin Corporation — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Lockheed Martin Corporation trades at $528.11 (market cap $123.44B). The key difference: Lockheed Martin Corporation is far larger — about 52.5× AbCellera Biologics Inc's market cap, and Lockheed Martin Corporation pays a 2.58% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LMT | |
|---|---|---|
Market Cap | $2.35B | $123.44B |
Sector | Health | Industrials |
52-Week High | $8.12 | $676.70 |
52-Week Low | $2.78 | $410.74 |
Enterprise Value | $1.99B | $142.24B |
Dividend Yield | — | 2.58% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
